Alpha 2.0
Login Register
» Authors » Juanita Lopez

Juanita Lopez

Explore the profile of Juanita Lopez including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 49
Citations 3479
Followers 0
Related Specialties
Oncology
General Medicine
Pharmacology
Top 10 Co-Authors
Udai Banerji
Johann de Bono
Nina Tunariu
Timothy A Yap
Anna Minchom
Johann S de Bono
Suzanne Carreira
Malaka Ameratunga
Ruth Riisnaes
Bora Gurel
Published In
Br J Cancer
Eur J Cancer
Clin Cancer Res
J Immunother Cancer
J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
11.
Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)
Pal A, Stapleton S, Yap C, Lai-Kwon J, Daly R, Magkos D, et al.
BMJ Open . 2021 Sep; 11(9):e049217. PMID: 34489282
Introduction: Early phase cancer clinical trials have become increasingly complicated in terms of patient selection and trial procedures-this is reflected in the increasing length of participant information sheets (PIS). Informed...
12.
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Yap T, Krebs M, Postel-Vinay S, El-Khouiery A, Soria J, Lopez J, et al.
Clin Cancer Res . 2021 Jul; 27(19):5213-5224. PMID: 34301752
Purpose: This study reports the safety, tolerability, MTD, recommended phase II dose (RP2D), pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of ceralasertib combined with carboplatin in patients with advanced solid tumors....
13.
HER3 expression and MEK activation in non-small-cell lung carcinoma
Manickavasagar T, Yuan W, Carreira S, Gurel B, Miranda S, Ferreira A, et al.
Lung Cancer Manag . 2021 Jun; 10(2):LMT48. PMID: 34084213
Aim: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression. Materials & Methods: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and...
14.
Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin
Marks D, Kucharczyk J, Kim P, Chyong D, Gartrell R, Lu Y, et al.
Cancer Invest . 2021 Jun; 39(6-7):466-472. PMID: 34075851
Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. Conventional pathology approaches have not identified a precise predictive biomarker for Eribulin. We performed qmIF on pre-treatment tissue from 11 patients (6...
15.
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
Falchook G, Infante J, Arkenau H, Patel M, Dean E, Borazanci E, et al.
EClinicalMedicine . 2021 Apr; 34:100797. PMID: 33870151
Background: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with...
16.
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience
Biondo A, Pal A, Riisnaes R, Shinde R, Tiu C, Lockie F, et al.
Cancer Treat Res Commun . 2021 Feb; 27:100309. PMID: 33549985
Early-phase cancer clinical trials are becoming increasingly accessible for patients with advanced cancer who have exhausted standard treatment options and later phase trial options. Many of these trials mandate research...
17.
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial
Reardon D, Kim T, Frenel J, Simonelli M, Lopez J, Subramaniam D, et al.
Cancer . 2021 Jan; 127(10):1620-1629. PMID: 33496357
Background: Current treatments for recurrent glioblastoma offer limited benefit. The authors report the antitumor activity and safety of the anti-programmed death 1 (anti-PD-1) immunotherapy, pembrolizumab, in programmed death ligand 1...
18.
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours
Robbrecht D, Lopez J, Calvo E, He X, Hiroshi H, Soni N, et al.
Br J Cancer . 2020 Oct; 124(2):391-398. PMID: 33020594
Background: This is a first-in-human study with TAS-119, an Aurora A kinase (AurA) inhibitor. Methods: Patients with advanced, refractory, solid tumours were enrolled into 5 dose escalation cohorts (70-300 mg...
19.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al.
Lancet Oncol . 2020 Sep; 21(10):1353-1365. PMID: 32919526
Background: Tumour mutational burden (TMB) has been retrospectively correlated with response to immune checkpoint blockade. We prospectively explored the association of high tissue TMB (tTMB-high) with outcomes in ten tumour-type-specific...
20.
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
Kristeleit R, Evans J, Molife L, Tunariu N, Shaw H, Slater S, et al.
Br J Cancer . 2020 Aug; 123(9):1360-1369. PMID: 32741975
Background: BAL101553 (lisavanbulin), the lysine prodrug of BAL27862 (avanbulin), exhibits broad anti-proliferative activity in human cancer models refractory to clinically relevant microtubule-targeting agents. Methods: This two-part, open-label, phase 1/2a study...